A retrospective study by Rogiers et al[51] demonstrated that the administration of combined anti-PD-1 and anti-CTLA-4 therapy was associated with increased hospitalization risk among cancer patients diagnosed with COVID-19 (OR 5.68, 95% CI 1.58–20.36, P = .027). Here, CTLA4 is linked to COVID-19.